UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Renal Transporters in Drug Development

Annual review of pharmacology and toxicology, 2013-01, Vol.53 (1), p.503-529

2013

Volltextzugriff (PDF)

OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin

Proceedings of the National Academy of Sciences - PNAS, 2014-07, Vol.111 (27), p.9983-9988

2014

Volltextzugriff (PDF)

Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling

Journal of medicinal chemistry, 2013-02, Vol.56 (3), p.781-795

2013

Volltextzugriff (PDF)

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

Breast cancer research : BCR, 2018-09, Vol.20 (1), p.109-12, Article 109

2018

Volltextzugriff (PDF)

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Journal for immunotherapy of cancer, 2018-06, Vol.6 (1), p.61-12, Article 61

2018

Volltextzugriff (PDF)

The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers

Clinical pharmacokinetics, 2016-04, Vol.55 (4), p.495-506

2016

Volltextzugriff (PDF)

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

Nature cancer, 2023-04, Vol.4 (4), p.485-501

2023

Volltextzugriff (PDF)

Genome-wide discovery of drug-dependent human liver regulatory elements

PLoS genetics, 2014-10, Vol.10 (10), p.e1004648

2014

Volltextzugriff (PDF)

First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

Clinical cancer research, 2020-04, Vol.26 (8), p.1820-1828

2020

Volltextzugriff (PDF)

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

Cancer chemotherapy and pharmacology, 2019-12, Vol.84 (6), p.1257-1267

2019

Volltextzugriff (PDF)

Computational analysis of kinase inhibitor selectivity using structural knowledge

Bioinformatics, 2019-01, Vol.35 (2), p.235-242

2019

Volltextzugriff (PDF)

Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor

British journal of clinical pharmacology, 2019-08, Vol.85 (8), p.1751-1760

2019

Volltextzugriff (PDF)

The Patient‐Centered Future of Clinical Pharmacology

Clinical pharmacology and therapeutics, 2020-01, Vol.107 (1), p.72-75

2020

Volltextzugriff (PDF)

Combining “Bottom‐up” and “Top‐down” Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC‐0941) Pharmacokinetics

CPT: pharmacometrics and systems pharmacology, 2017-11, Vol.6 (11), p.747-755

2017

Volltextzugriff (PDF)

The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin

Clinical pharmacology and therapeutics, 2013-02, Vol.93 (2), p.186-194

2013

Volltextzugriff (PDF)

Expanding the Role of the Dynein Regulatory Complex to Non‐Axonemal Functions: Association of GAS11 with the Golgi Apparatus

Traffic (Copenhagen, Denmark), 2006-05, Vol.7 (5), p.538-548

2006

Volltextzugriff (PDF)

Genome-Wide Discovery of Drug-Dependent Human Liver Regulatory Elements: e1004648

PLoS genetics, 2014-10, Vol.10 (10)

2014

Volltextzugriff (PDF)

Phase Ia study of the indoleamine 2,3-dioxygenase 1 in patients with recurrent advanced solid tumors

Journal for immunotherapy of cancer, 2018-06, Vol.6 (1)

2018

Volltextzugriff (PDF)

Organic Cation Transporters in Drug Disposition and Response

Morrissey, Kari M

2013

Volltextzugriff (PDF)

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer

European journal of cancer (1990), 2017-11, Vol.86, p.186-196

2017

Volltextzugriff (PDF)

Consequences of POR mutations and polymorphisms

Molecular and cellular endocrinology, 2011-04, Vol.336 (1-2), p.174-179

2011

Volltextzugriff (PDF)

Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro

Pharmacogenetics and genomics, 2010-11, Vol.20 (11), p.677-686

2010

Volltextzugriff (PDF)

A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.105-105

2017

Volltextzugriff (PDF)

Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping

The pharmacogenomics journal, 2012-06, Vol.12 (3), p.214-226

2012

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(23)
Dissertationen
(1)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Renal Transporters in Drug Development

OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin

Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

Genome-wide discovery of drug-dependent human liver regulatory elements

First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

Computational analysis of kinase inhibitor selectivity using structural knowledge

Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor

The Patient‐Centered Future of Clinical Pharmacology

Combining “Bottom‐up” and “Top‐down” Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC‐0941) Pharmacokinetics

The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin

Expanding the Role of the Dynein Regulatory Complex to Non‐Axonemal Functions: Association of GAS11 with the Golgi Apparatus

Genome-Wide Discovery of Drug-Dependent Human Liver Regulatory Elements: e1004648

Phase Ia study of the indoleamine 2,3-dioxygenase 1 in patients with recurrent advanced solid tumors

Organic Cation Transporters in Drug Disposition and Response

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer

Consequences of POR mutations and polymorphisms

Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro

A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors

Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping

Suchergebnisse filtern